Crinetics Pharmaceuticals Inc (CRNX) - Total Liabilities
Based on the latest financial reports, Crinetics Pharmaceuticals Inc (CRNX) has total liabilities worth $120.68 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Crinetics Pharmaceuticals Inc growing its equity to track the company's year-over-year net asset growth rate.
Crinetics Pharmaceuticals Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how Crinetics Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data.
Crinetics Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Crinetics Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Henan Zhongfu Industrial Co Ltd
SHG:600595
|
China | CN¥7.59 Billion |
|
Cosan SA ADR
NYSE:CSAN
|
USA | $97.60 Billion |
|
Griffon Corporation
NYSE:GFF
|
USA | $1.97 Billion |
|
Banco del Bajío S.A. Institución de Banca Múltiple
MX:BBAJIOO
|
Mexico | MX$344.55 Billion |
|
Caesars Entertainment Corporation
NASDAQ:CZR
|
USA | $27.93 Billion |
|
Mueller Water Products
NYSE:MWA
|
USA | $814.00 Million |
|
Trex Company Inc
NYSE:TREX
|
USA | $734.05 Million |
|
Allete Inc
NYSE:ALE
|
USA | $3.81 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Crinetics Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Crinetics Pharmaceuticals Inc (CRNX) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 18.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Crinetics Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Crinetics Pharmaceuticals Inc (2016–2025)
The table below shows the annual total liabilities of Crinetics Pharmaceuticals Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $143.41 Million | +30.63% |
| 2024-12-31 | $109.79 Million | +14.07% |
| 2023-12-31 | $96.25 Million | +168.49% |
| 2022-12-31 | $35.85 Million | +87.97% |
| 2021-12-31 | $19.07 Million | +31.29% |
| 2020-12-31 | $14.53 Million | +9.73% |
| 2019-12-31 | $13.24 Million | +18.30% |
| 2018-12-31 | $11.19 Million | -63.46% |
| 2017-12-31 | $30.62 Million | +62.85% |
| 2016-12-31 | $18.80 Million | -- |
About Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acrome… Read more